Literature DB >> 32550987

Assembling Pharma Resources to Tackle Diseases of Underserved Populations.

Dale J Kempf1, Kennan C Marsh1.   

Abstract

Tropical diseases that disproportionally affect the world's poorest people have traditionally been neglected from research efforts toward the discovery and development of new and effective therapies. Over the past two decades, major global health funders have made efforts to bring together various research institutions to work together in these disease areas offering little or no commercial return. This work describes the genesis and growth of an informal program devoted to contributing to new therapies for neglected tropical diseases within the environment of a major biopharmaceutical company (AbbVie).
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 32550987      PMCID: PMC7294558          DOI: 10.1021/acsmedchemlett.0c00051

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  52 in total

1.  The role of Product Development Partnerships in research and development for neglected diseases.

Authors:  M Moran; J Guzman; A L Ropars; A Illmer
Journal:  Int Health       Date:  2010-06       Impact factor: 2.473

Review 2.  Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis.

Authors:  María-Gloria Basáñez; Sébastien D S Pion; Eve Boakes; João A N Filipe; Thomas S Churcher; Michel Boussinesq
Journal:  Lancet Infect Dis       Date:  2008-05       Impact factor: 25.071

3.  UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria.

Authors:  Christel Brunschwig; Nina Lawrence; Dale Taylor; Efrem Abay; Mathew Njoroge; Gregory S Basarab; Claire Le Manach; Tanya Paquet; Diego Gonzàlez Cabrera; Aloysius T Nchinda; Carmen de Kock; Lubbe Wiesner; Paolo Denti; David Waterson; Benjamin Blasco; Didier Leroy; Michael J Witty; Cristina Donini; James Duffy; Sergio Wittlin; Karen L White; Susan A Charman; Maria Belén Jiménez-Díaz; Iñigo Angulo-Barturen; Esperanza Herreros; Francisco Javier Gamo; Rosemary Rochford; Dalu Mancama; Theresa L Coetzer; Mariëtte E van der Watt; Janette Reader; Lyn-Marie Birkholtz; Kennan C Marsh; Suresh M Solapure; John E Burke; Jacob A McPhail; Manu Vanaerschot; David A Fidock; Paul V Fish; Peter Siegl; Dennis A Smith; Grennady Wirjanata; Rintis Noviyanti; Ric N Price; Jutta Marfurt; Kigbafori D Silue; Leslie J Street; Kelly Chibale
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

4.  2nd SCI/RSC Symposium on Medicinal Chemistry for Global Health: A Unique Opportunity for the Field.

Authors:  Courtney C Aldrich; Félix Calderón
Journal:  ACS Infect Dis       Date:  2018-04-13       Impact factor: 5.084

5.  Potent and selective inhibitors of CDPK1 from T. gondii and C. parvum based on a 5-aminopyrazole-4-carboxamide scaffold.

Authors:  Zhongsheng Zhang; Kayode K Ojo; Ramasubbarao Vidadala; Wenlin Huang; Jennifer A Geiger; Suzanne Scheele; Ryan Choi; Molly C Reid; Katelyn R Keyloun; Kasey Rivas; Latha Kallur Siddaramaiah; Kenneth M Comess; Kenneth P Robinson; Philip J Merta; Lemma Kifle; Wim G J Hol; Marilyn Parsons; Ethan A Merritt; Dustin J Maly; Christophe L M J Verlinde; Wesley C Van Voorhis; Erkang Fan
Journal:  ACS Med Chem Lett       Date:  2014-01-09       Impact factor: 4.345

Review 6.  Development of Mycobacterium tuberculosis whole cell screening hits as potential antituberculosis agents.

Authors:  Christopher B Cooper
Journal:  J Med Chem       Date:  2013-09-23       Impact factor: 7.446

7.  A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria.

Authors:  Margaret A Phillips; Julie Lotharius; Kennan Marsh; John White; Anthony Dayan; Karen L White; Jacqueline W Njoroge; Farah El Mazouni; Yanbin Lao; Sreekanth Kokkonda; Diana R Tomchick; Xiaoyi Deng; Trevor Laird; Sangeeta N Bhatia; Sandra March; Caroline L Ng; David A Fidock; Sergio Wittlin; Maria Lafuente-Monasterio; Francisco Javier Gamo Benito; Laura Maria Sanz Alonso; Maria Santos Martinez; Maria Belen Jimenez-Diaz; Santiago Ferrer Bazaga; Iñigo Angulo-Barturen; John N Haselden; James Louttit; Yi Cui; Arun Sridhar; Anna-Marie Zeeman; Clemens Kocken; Robert Sauerwein; Koen Dechering; Vicky M Avery; Sandra Duffy; Michael Delves; Robert Sinden; Andrea Ruecker; Kristina S Wickham; Rosemary Rochford; Janet Gahagen; Lalitha Iyer; Ed Riccio; Jon Mirsalis; Ian Bathhurst; Thomas Rueckle; Xavier Ding; Brice Campo; Didier Leroy; M John Rogers; Pradipsinh K Rathod; Jeremy N Burrows; Susan A Charman
Journal:  Sci Transl Med       Date:  2015-07-15       Impact factor: 17.956

8.  Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.

Authors: 
Journal:  Lancet       Date:  2016-10-08       Impact factor: 79.321

Review 9.  Drug discovery and development for neglected diseases: the DNDi model.

Authors:  Eric Chatelain; Jean-Robert Ioset
Journal:  Drug Des Devel Ther       Date:  2011-03-16       Impact factor: 4.162

10.  Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus.

Authors:  Mike Y Osei-Atweneboana; Kwablah Awadzi; Simon K Attah; Daniel A Boakye; John O Gyapong; Roger K Prichard
Journal:  PLoS Negl Trop Dis       Date:  2011-03-29
View more
  1 in total

Review 1.  Onchocerciasis drug development: from preclinical models to humans.

Authors:  Adela Ngwewondo; Ivan Scandale; Sabine Specht
Journal:  Parasitol Res       Date:  2021-10-13       Impact factor: 2.289

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.